Eikon Therapeutics Inc. (EIKN), a late-stage biopharmaceutical company, on Monday released its first quarter financial results, and provided clinical updates.
Q1 2026:
The company recorded a net loss of $83 million in Q1 2026, while in the same period of 2025, the net loss was $74.5million.
Research and development expenses (R&D) were $70 million, a 24% increase from the $56.6 million reported in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $596 million. The available capital is expected to fund company operations till 2027.
Clinical Updates:
EIK1001 is a dual-agonist of Toll-like receptors 7 and 8 that stimulates both the innate and adaptive immune responses to treat advanced malignancies. The company plans to present updated Phase 2 data for EIK1001 in combination with pembrolizumab and chemotherapy for the treatment of non-small cell lung cancer (NSCLC), and Phase 2/3 data for EIK1001 in combination with pembrozulimab for treating advanced melanoma at the American Society of Clinical Oncology ("ASCO") annual meeting.
. A Phase 2/3 trial was also initiated for EIK1001 in combination with pembrolizumab and chemotherapy for the treatment of stage 4 NSCLC.
EIK1003 is a next-generation, highly selective PARP1 inhibitor currently being advanced in a Phase 1/2 trial for patients with breast, ovarian, prostate, or pancreatic cancer. The company reported dosing of the first patient in a Phase 2 dose optimization trial. Site selection was also initiated for Cohort 1D, which will evaluate EIK1003 in combination with paclitaxel and platinum-based chemotherapeutic agents to treat breast or ovarian cancer.
EIK1005 is a WRN helicase inhibitor developed to treat microsatellite instability (MSI) cancers. A Phase 1/2 trial to treat patients with advanced solid tumors was initiated in February 2026.
EIKN closed Monday at $9.95, up 0.35%. In the pre-market, shares are trading at $10.90, up 9.55%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.